Trial Profile
A Phase I/II Trial of SCIB1, a DNA Immunotherapy, in the Treatment of Patients With Malignant Melanoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs SCIB 1 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Scancell
- 11 Jul 2017 5 year survival results published in the Media Release
- 30 Jan 2017 Status changed from active, no longer recruiting to completed, as per a Scancell Holdings PLC media release.
- 21 Jul 2016 According to a Scancell media release, the clinical trial material will be available in approximately 9-12 months to recommence dosing of patients in the long-term extension of the Phase.